These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 15269478)
1. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478 [TBL] [Abstract][Full Text] [Related]
2. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536 [TBL] [Abstract][Full Text] [Related]
4. Microvessel density in brain tumors. Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Papadakis N; Varakis I Anticancer Res; 1997; 17(6D):4747-53. PubMed ID: 9494601 [TBL] [Abstract][Full Text] [Related]
5. The expression of cell cycle regulatory proteins in oligodendroglial tumors. Kamiya M; Nakazato Y Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253 [TBL] [Abstract][Full Text] [Related]
6. Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry. Badhe PB; Chauhan PP; Mehta NK Indian J Cancer; 2004; 41(4):170-4. PubMed ID: 15659871 [TBL] [Abstract][Full Text] [Related]
7. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
8. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Lang FF; Miller DC; Pisharody S; Koslow M; Newcomb EW Oncogene; 1994 Mar; 9(3):949-54. PubMed ID: 8108140 [TBL] [Abstract][Full Text] [Related]
9. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Sasaki T; Lopes MB; Hankins GR; Helm GA Acta Neuropathol; 2002 Jul; 104(1):105-9. PubMed ID: 12070671 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of malignant features in oligodendroglial tumors. Saito A; Nakazato Y Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. Prayson RA; Mohan DS; Song P; Suh JH Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299 [TBL] [Abstract][Full Text] [Related]
13. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078 [TBL] [Abstract][Full Text] [Related]
14. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609 [TBL] [Abstract][Full Text] [Related]
15. p53 mutation and protein alteration in 50 gliomas. Retrospective study by DNA-sequencing techniques and immunohistochemistry. von Eckardstein K; Gries H; Bolik E; Cervós-Navarro J; Tschairkin IN; Patt S Histol Histopathol; 1997 Jul; 12(3):611-6. PubMed ID: 9225141 [TBL] [Abstract][Full Text] [Related]
16. [Histological and molecular classification of gliomas]. Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348 [TBL] [Abstract][Full Text] [Related]
17. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874 [TBL] [Abstract][Full Text] [Related]
18. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. Erdamar S; Bagci P; Oz B; Dirican A J BUON; 2006; 11(2):213-6. PubMed ID: 17318973 [TBL] [Abstract][Full Text] [Related]
19. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Thorns V; Walter GF; Thorns C Anticancer Res; 2003; 23(5A):3937-44. PubMed ID: 14666700 [TBL] [Abstract][Full Text] [Related]
20. Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Haapasalo H; Isola J; Sallinen P; Kalimo H; Helin H; Rantala I Am J Pathol; 1993 May; 142(5):1347-51. PubMed ID: 7684193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]